Kapstone Financial Advisors LLC Gilead Sciences, Inc. Transaction History
Kapstone Financial Advisors LLC
- $201 Billion
- Q2 2025
A detailed history of Kapstone Financial Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Kapstone Financial Advisors LLC holds 1,891 shares of GILD stock, worth $221,587. This represents 0.1% of its overall portfolio holdings.
Number of Shares
1,891
Previous 1,891
-0.0%
Holding current value
$221,587
Previous $212 Million
1.05%
% of portfolio
0.1%
Previous 0.12%
Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
2,330Shares Held
1.03BCall Options Held
12.1MPut Options Held
9.13M-
Black Rock Inc. New York, NY121MShares$14.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$6.94 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.43 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.4 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $147B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...